Article

Metabolic syndrome more prevalent in heart-healthy patients with RA

Among patients who do not have cardiovascular disease (CVD), the prevalence of metabolic syndrome is higher in those who have rheumatoid arthritis (RA) than in those who do not. Metabolic syndrome in RA is associated with greater disability and a history of large-joint swelling but not with RA therapy.

Among patients who do not have cardiovascular disease (CVD), the prevalence of metabolic syndrome is higher in those who have rheumatoid arthritis (RA) than in those who do not. Metabolic syndrome in RA is associated with greater disability and a history of large-joint swelling but not with RA therapy.

Crowson and coworkers conducted a community population-based study using the Rochester Epidemiology Project. Their population sample included 232 patients with RA and no CVD and 1241 persons who had no RA or CVD. Patients in both cohorts completed a CVD risk factor and medication use questionnaire, underwent a physical examination, and provided a blood sample. Medical records were reviewed.

Metabolic syndrome was present in 33% of patients who had RA compared with 25% of patients who did not-a gap that widened after adjusting for age and sex. Persons with RA had bigger waistlines, a difference that became increased after adjusting for body mass index. They also had higher blood pressure, but their lipid profiles were similar. They also had more disability and large-joint swelling.

The authors noted that recognition of metabolic syndrome in patients with RA in whom CVD has not yet developed could provide a valuable opportunity for preventive intervention.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.